Takeda Pharmaceutical Company Limited (LON:0A87)
London flag London · Delayed Price · Currency is GBP · Price in USD
15.89
0.00 (0.00%)
At close: Jan 20, 2026

LON:0A87 Income Statement

Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Mar '25 Mar '24 Mar '23 Mar '22 Mar '21
4,464,5784,581,5514,263,7624,027,4783,569,0063,197,812
Revenue Growth (YoY)
-2.50%7.45%5.87%12.85%11.61%-2.84%
Cost of Revenue
1,539,1641,571,4191,431,5051,253,1631,127,3081,013,655
Gross Profit
2,925,4143,010,1322,832,2572,774,3152,441,6982,184,157
Selling, General & Admin
1,088,0511,104,7321,053,819997,234886,327875,514
Research & Development
696,610730,226728,617633,325526,087455,765
Amortization of Goodwill & Intangibles
533,435548,186521,525485,102418,789405,229
Other Operating Expenses
4,11764,05228,82138,98710,43323,602
Operating Expenses
2,322,2132,447,1962,332,7822,154,6481,841,6361,760,110
Operating Income
603,201562,936499,475619,667600,062424,047
Interest Expense
-130,487-130,487-115,392-116,973-122,432-130,806
Interest & Investment Income
198,20319,98311,6285,7814,7632,153
Earnings From Equity Investments
-2,603-3,9866,473-8,630-15,36776
Currency Exchange Gain (Loss)
786786-13,612-9,729-3,903-15,575
Other Non Operating Income (Expenses)
-159,648-24,865-31,5203,975-26,1191,118
EBT Excluding Unusual Items
509,452424,367357,052494,091437,004281,013
Merger & Restructuring Charges
-128,133-128,133-81,358-59,234-83,836-115,875
Gain (Loss) on Sale of Investments
-38,285-18,885-22,4168,482-
Gain (Loss) on Sale of Assets
28,46110,5617,9758,9018,164235,117
Asset Writedown
-156,679-103,379-146,047-62,484-54,421-17,521
Legal Settlements
---45,212-16,455-20,319-17,401
Other Unusual Items
-9,447-9,447-39,619-12,1457,497902
Pretax Income
205,369175,08452,791375,090302,571366,235
Income Tax Expense
92,18466,941-91,40658,05272,405-9,936
Earnings From Continuing Operations
113,185108,143144,197317,038230,166376,171
Minority Interest in Earnings
-259-215-130-21-107-166
Net Income
112,926107,928144,067317,017230,059376,005
Net Income to Common
112,926107,928144,067317,017230,059376,005
Net Income Growth
-45.73%-25.09%-54.55%37.80%-38.81%749.90%
Shares Outstanding (Basic)
1,5751,5791,5641,5521,5641,562
Shares Outstanding (Diluted)
1,6021,6051,5801,5701,5771,574
Shares Change (YoY)
0.25%1.58%0.67%-0.46%0.23%0.47%
EPS (Basic)
71.6968.3692.09204.29147.14240.72
EPS (Diluted)
70.4767.2391.16201.94145.87238.96
EPS Growth
-45.86%-26.25%-54.86%38.44%-38.96%745.88%
Free Cash Flow
1,010,628856,387540,924836,499999,853899,725
Free Cash Flow Per Share
630.67533.47342.28532.85633.95571.78
Dividend Per Share
198.000196.000188.000180.000180.000180.000
Dividend Growth
3.13%4.25%4.44%---
Gross Margin
65.53%65.70%66.43%68.88%68.41%68.30%
Operating Margin
13.51%12.29%11.71%15.39%16.81%13.26%
Profit Margin
2.53%2.36%3.38%7.87%6.45%11.76%
Free Cash Flow Margin
22.64%18.69%12.69%20.77%28.02%28.14%
EBITDA
1,273,9571,233,2621,143,9361,284,0671,183,213983,718
EBITDA Margin
28.54%26.92%26.83%31.88%33.15%30.76%
D&A For EBITDA
670,756670,326644,461664,400583,151559,671
EBIT
603,201562,936499,475619,667600,062424,047
EBIT Margin
13.51%12.29%11.71%15.39%16.81%13.26%
Effective Tax Rate
44.89%38.23%-15.48%23.93%-
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.